Beirunning Appears at Zhejiang Ophthalmology Annual Meeting


Release time:

2019-11-21

11Month15Day-17On the same day, the annual meeting of the Zhejiang Society of Integrated Traditional Chinese and Western Medicine was held in Huzhou, Zhejiang Province. Peak Pharmaceutical Company took its products to the annual meeting and introduced Berunning (Olopatadine Hydrochloride Eye Drops), the first product in China that passed the consistency evaluation.

The annual meeting was co-sponsored by the Visual Function Professional Committee of Zhejiang Rehabilitation Medicine Association, the Ophthalmology Professional Committee of Zhejiang Integrated Traditional Chinese and Western Medicine Association, and the Ophthalmology Professional Committee of Huzhou Medical Association. "New progress in diagnosis and treatment of functional rehabilitation", provincial continuing medical education class "diagnosis and treatment of difficult diseases in ophthalmology", and provincial continuing medical education class "integrated traditional Chinese and western medicine prevention and treatment of diabetic retinopathy.

At this annual meeting, the pharmaceutical company invited Zhang Huicheng, president of Hangzhou Qiushi Hospital and former president of the ophthalmology annual meeting of Zhejiang Integrated Traditional Chinese and Western Medicine Association, to introduce Jianfeng Pharmaceutical and Berunning products. He introduced in detail the causes of allergy, how to choose anti-eye allergy drugs, why to choose anti-allergy drugs with double-effect mechanism, and why to choose Berunning Olopatadine Hydrochloride Eye Drops of Zhejiang Jianfeng Pharmaceutical Co., Ltd. Berunning is the first eye drops to pass the consistency evaluation in China, and by virtue of its antagonistic histamine H1-The unique efficacy of stabilizing mast cells in two-way anti-allergy has received widespread attention. Beirunning in the treatment of children with allergic conjunctivitis has good effect, fast curative effect, will not cause significant mast cell degranulation, so the use of more safe, and almost no adverse reactions to the eye tissue, is the current treatment of allergic conjunctivitis an ideal drug. Beirunning products have been unanimously recognized and praised by on-site ophthalmologists.

Participating in this annual meeting has improved the recognition of Berunning in the group of ophthalmologists in Zhejiang, and laid a good foundation for the market promotion of Berunning in the later period.